Physician profile
Robert C Strayhan
NPI 1023178043
$6,202.75
in general payments reported to CMS, 2019-2025
22 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $436 · 2021: $424 · 2022: $667 · 2023: $1,718 · 2024: $1,866 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,121.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,346.02 | 2022-2025 | Vraylar, Botox |
| Janssen Pharmaceuticals, INC | $627.48 | 2019-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $539.01 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $509.86 | 2019-2025 | Ingrezza |
| Allergan, INC. | $496.37 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $311.77 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $198.12 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $191.83 | 2019-2024 | Dyanavel Xr |
| Lundbeck LLC | $190.06 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $180.58 | 2019-2023 | Jornay Pm |
| Eisai INC. | $150.54 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $138.86 | 2019-2024 | Uzedy |
| Vanda Pharmaceuticals INC. | $81.64 | 2020-2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $58.74 | 2021-2024 | Trintellix |
| Neos Therapeutics, Lp | $43.01 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $31.07 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $22.69 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $22.62 | 2019-2021 | |
| Livanova USA, INC. | $19.58 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Sunovion Pharmaceuticals INC. | $19.18 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.17 | 2019 | |
| Shire North American Group INC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Strayhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.